Trust Company of Vermont’s Juno Therapeutics, Inc. JUNO Stock Holding History

Trust Company of Vermont’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-145	Closed	-$7K	–	1015
2017 Q4	$7K	Hold	145	–	–	﹤0.01%	812
2017 Q3	$7K	Hold	145	–	–	﹤0.01%	775
2017 Q2	$4K	Hold	145	–	–	﹤0.01%	867
2017 Q1	$3K	Hold	145	–	–	﹤0.01%	825
2016 Q4	$3K	Hold	145	–	–	﹤0.01%	826
2016 Q3	$4K	Hold	145	–	–	﹤0.01%	762
2016 Q2	$6K	Hold	145	–	–	﹤0.01%	687
2016 Q1	$6K	Buy	+145	New	+$5.05K	﹤0.01%	640

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Trust Company of Vermont's JUNO Position: Q1 2018 in Review

Trust Company of Vermont sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 145 shares — an estimated $7K sold.

Trust Company of Vermont first reported a position in JUNO in Q1 2016 and held it in 8 quarters. The position peaked at $7K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Trust Company of Vermont reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Trust Company of Vermont sold 145 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $7K.
Trust Company of Vermont first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Trust Company of Vermont's Juno Therapeutics, Inc. position peaked at $7K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Trust Company of Vermont's 13F filing for Q1 2018, filed 18 May 2018.